Unichem Laboratories Ltd.
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in India, the United States, and internationally. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services. In addition, the company manufactures allopathic medicines, bulk drugs, and chemicals. It serves patients, distributors, health care professionals, and government institutions. The company was founded in 1944 and is based in Mumbai, India. Unichem Laboratories Limited is a subsidiary of Ipca Laboratories Limited.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Revenue grew 20.4% YoY
Concerns1
- Negative free cash flow (₹65 Cr)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (₹ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (₹ Crores, last 1 year)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | ₹1.74 K Cr | — | ₹163.00 Cr | — | — | 6.6% | 20.4% | -277.2% |
Showing the latest year only. Sign up free for the full history.
Financial Statements
Income statement, balance sheet, and cash flow (₹ Crores, as reported)
Showing the latest year only. Sign up free for the full history.
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 1,650 |
| Total Expenses | 1,468 |
| EBIT / Operating Profit | 183 |
| OPM % | 11% |
| Other Income | 21 |
| Finance Costs | 10 |
| Depreciation & Amortisation | 116 |
| Profit Before Tax | 78 |
| Tax % | - |
| Net Profit / PAT | 56 |
| EPS (₹) | 8 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Unichem Laboratories Ltd.this co. | ₹2.90 K Cr | ₹1.74 K Cr | 34.60 | 1.20 | 111.38 | 20.4% |
| Sun Pharmaceutical Industries Ltd. | ₹4.15 L Cr | ₹23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | ₹1.71 L Cr | ₹9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | ₹1.33 L Cr | ₹9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | ₹1.17 L Cr | ₹19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | ₹1.05 L Cr | ₹8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | ₹1.00 L Cr | ₹2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | — | ₹3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |